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Visit-to-visit variability (VVV) of blood pressure is associ-
ated with cardiovascular disease. The authors examined
the effects of visit number and timing and automated or
manual measurement device on VVV in the placebo arm of
the Trial of Preventing Hypertension (TROPHY) (N=225)
and simulations. VVV was assessed using intra-individual
standard deviation (SD), range, maximum, coefficient of
variation, successive variation, and average real variability
of systolic blood pressure. VVV increased with number of
visits used to calculate it in the TROPHY population (P for
trend <.05 for all metrics) and simulations. Using consecu-
tive visits in TROPHY, average SD was 5.6 mm Hg from 3
visits, 6.8 mm Hg from 7 visits, and 7.7 mm Hg from 18
visits. When 7 visits were spread out across 4 years, the
average SD was higher (7.5 mm Hg) than when visits were
consecutive over 18 months (P<.001). SD was higher
using a single blood pressure measurement per visit (com-
pared with the mean of 3 measurements per visit P<.001)
and with automated vs manual devices (P<.001). In sum-
mary, number and timing of visits and device used to
measure blood pressure influence VVV and need to be
considered when designing, interpreting, and comparing
studies. J Clin Hypertens (Greenwich). 2012;14:744–750.
2012 Wiley Periodicals, Inc.
Associations between visit-to-visit variability (VVV) of
systolic blood pressure (SBP) and stroke, coronary
heart disease, and mortality have been reported in sev-
eral recent publications.1–5 In one study, VVV had a
stronger association with cardiovascular events than
mean blood pressure (BP).3 This has inspired a great
deal of interest in VVV as a novel risk factor for car-
diovascular disease independent of mean BP. Antihy-
pertensive medication classes have differential effects
on VVV that parallel their effects on outcomes, sug-
gesting that cardiovascular events could potentially be
prevented by switching patients to antihypertensive
medications that reduce VVV.2,6,7
VVV is a relatively new risk factor, however, and
methods for assessing VVV have not been standard-
ized. To investigate the effects of VVV on cardiovas-
cular and mortality outcomes, investigators have
used existing BP data from clinical trials and estab-
lished cohorts.1–5 The number and timing of BP
measurements and the BP measurement protocols
have differed from study to study. For example,
some populations had one BP measurement per visit
while others averaged multiple measurements.1–5
Some of the prior studies have used automated BP
measurement while others relied on manual BP mea-
surement.1–5 The minimal number of measurements
needed to reliably estimate an individual’s VVV is
not known, and the impact of the time between vis-
its on VVV has not been extensively studied. Prior
studies have examined the association of VVV and
outcomes using as few as 3 visits while other studies
have used more visits. In addition, the effect of
automated vs manual BP measurement device and
number of BPs per visit on VVV is unclear. Informa-
tion regarding the effects of BP assessment on VVV
is necessary to appropriately design, interpret, and
compare studies of VVV.
We therefore examined the effect of the number and
timing of BP measurements and BP measurement
device on VVV using data from the placebo arm of
the Trial of Preventing Hypertension (TROPHY) and
from simulation studies. In TROPHY, BP was mea-
sured every 1 to 3 months for 4 years. The simulation
studies allowed us to examine the effect of the number
of visits on VVV without complicating factors such as
change in mean BP over time.
METHODS
Study Population
The design and results of the TROPHY trial have been
presented previously.8,9 Briefly, men and women aged
30 to 65 years with high-normal BP (average
systolic ⁄ diastolic BP over 3 baseline visits of 130–
139 ⁄89 mm Hg or 139 ⁄ 85–89 mm Hg) were
randomized to 16 mg ⁄ d of candesartan (n=391) or
placebo (n=381). After 2 years of follow-up, the active
treatment group was switched to placebo. The primary
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endpoint was a composite of 3 visits with SBP
140 mm Hg or diastolic BP 90 mm Hg, 1 visit
with SBP 160 mm Hg or diastolic BP 100 mm Hg,
or target organ damage or other clinical reasons to
start antihypertensive therapy as determined by the
investigators. If a participant reached the endpoint,
open-label antihypertensive treatment was initiated.
Treatment with metoprolol or hydrochlorothiazide
was provided to participants at no cost, but other
medications, with the exception of angiotensin recep-
tor blockers, could also be used. For this analysis, we
included the 225 participants randomized to placebo
who completed all 18 postbaseline visits. Institutional
review boards at all participating centers approved
the TROPHY protocol, and all participants provided
written informed consent.
BP Measurement
At each clinic visit, BP was measured after 5 minutes
of rest using a standardized protocol. BP was mea-
sured 3 times using an automated device (HEM-
705CP; Omron Healthcare, Kyoto, Japan) and 3 times
using a manual device. The order of the automated
and manual BP measurement and the specific manual
BP measurement device used were not specified in the
TROPHY protocol.
Calculation of VVV of SBP
Although several metrics of VVV have been proposed,
we focused on the intra-individual standard deviation
(SD) of SBP because it has been previously associated
with cardiovascular events and mortality1,3 and it is
easy to calculate and interpret. Because BP at the 3
baseline visits determined eligibility for study entry and
was constrained to a narrow range, BP measurements
from these visits were not used in any of the analyses.
We calculated the BP at each visit using 4 different
approaches: the mean of the 3 automated BP measure-
ments, the first automated BP measurement, the mean
of the 3 manual BP measurements, and the first manual
BP measurement. Intra-individual SD was calculated
using the formula SD ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiPn
i¼1
ðxi  xÞ2=ðn 1Þ
s
. In this
formula, n is the number of visits, xi is the individual’s
BP at visit i (the mean of 3 measurements or the first
measurement), and x is the individual’s average BP
across visits. To examine whether the number of BP
measurements influences the intra-individual SD, we
calculated the intra-individual SD using the first 3
postbaseline visits, first 4 postbaseline visits, and up to
all 18 postbaseline visits. Additionally, we calculated
the intra-individual SD from 7 measurements spaced
out across the 4-year follow-up period.
To examine whether the number of visits influences
other metrics of VVV, we calculated the range, the max-
imum, the coefficient of variation, the successive varia-
tion, and the average real variability using the mean of
3 manual BP measurements per visit. The coefficient of
variation was calculated as SD=x, the successive varia-












jxiþ1  xijÞ=ðn 1Þ:
Statistical Analysis
We first calculated means and SD or percentages of
baseline characteristics of the TROPHY participants
randomized to placebo by whether they initiated antihy-
pertensive medications during the study period. We
computed the correlations between intra-individual SD
calculated from 7 visits using the mean of the 3 auto-
mated BP measurements per visit, the first automated
BP measurement per visit, the mean of the 3 manual BP
measurements per visit, and the first manual BP mea-
surement per visit. We chose to examine the intra-
individual SD calculated from 7 visits as this has been
used in previous studies.3,10 We compared the SD
between participants who did and did not initiate anti-
hypertensive medications using t tests. Additionally, we
calculated the SD of SBP including only those measure-
ments taken prior to the initiation of antihypertensive
medications. For these calculations, an individual who
initiated antihypertensive medications after 5 visits
would have an SD calculated from 5 visits, would be
censored after 5 visits, and would not have SDs calcu-
lated from 6 to 18 visits. We tested for the statistical sig-
nificance of differences in SD calculated from 7 visits
with automated vs manual devices and using 1 vs the
mean of 3 BP measurements per visit using paired t
tests. Tests of trend in SD and other VVV metrics by
number of visit were performed using generalized esti-
mating equations. To compare the intra-individual SD
calculated using a limited number of visits (3–10 visits)
with the intra-individual SD calculated using all 18 vis-
its, we computed the percent difference as 100%
j SDn  SD18 j =SD18 where SDn is the intra-individual
SD calculated from n visits and SD18 is the intra-
individual SD calculated from 18 visits. We tested for
differences between SD calculated from 7 consecutive
visits and 7 visits spread out across follow-up visit using
paired t tests.
Simulation Study
To evaluate how the number of visits affects the intra-
individual SD under ideal conditions of known ‘‘true’’
mean and intra-individual SD, we created simulated
populations of 200 individuals and BP measurements
from 100 visits. SBP was assumed to be normally dis-
tributed where all individuals had a mean SBP of
135 mm Hg and an intra-individual SD of 8.5 mm Hg.
In the first simulated population, we assumed that BP
measurements were uncorrelated between visits. We
then modeled an autoregressive correlation structure,
which assumed BP measurements were more closely
correlated in adjacent visits with the correlation
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decreasing over time.11 In this correlation structure,
adjacent visits had a correlation of r, a pair of visits with
one intervening visit had a correlation of r2, a pair of
visits with 2 intervening visits had a correlation of r3,
and so on. We examined simulated populations with
autocorrelation coefficients of 0.3, 0.5, and 0.7. As in
the TROPHY study population, we calculated the intra-
individual SD across visits (n=3–100). In the simulated
population, we used a fractional polynomial algo-
rithm12 to examine the shape of the association between
the intra-individual SD and the number of visits. Frac-
tional polynomials take the form Xp+Xq where X is the
variable of interest, in this case the number of visits.
The powers p and q were chosen from the set of possible
values )2, )1, )0.5, natural logarithm, 0.5, 1, 2, and 3
based on the best fit to the data. If p=q then the model is
Xp+Xp ln(X). We also explored simpler polynomial
curves within smaller, more plausible ranges of number
of visits. Additionally, we examined the SD from 7 con-
secutive visits and 7 visits spaced throughout the 100
simulated visits. Analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC) and Stata version
11.2 (StataCorp, College Station, TX).
RESULTS
Study Population
Of the 225 participants in the TROPHY placebo arm
who completed all 18 postbaseline study visits, 138
(61%) initiated antihypertensive medications during
follow-up and 87 (39%) did not. There were no major
differences in baseline characteristics between those
who did and did not initiate antihypertensive medica-
tions (Table I).
BP Measurement Technique and Intra-Individual
SD
Correlations between intra-individual SD from 7 visits
calculated from the first measurement per visit and the
mean of 3 measurements per visit using the same type
of device were high (r=0.85–0.94), but the correlations
between intra-individual SD calculated from auto-
mated vs manual devices were lower (0.49–0.67)
(Table II). In the overall TROPHY population, regard-
less of the number of visits used, intra-individual SD
calculated using automated BP measurement was
higher than manual measurement (P<.001 for SD cal-
culated from 7 visits) (Table III). For both automated
and manual measurements, using the first measure-
ment taken at each visit resulted in a higher intra-indi-
vidual SD compared with using the mean of 3
measurements taken at each visit (P<.001 for SD cal-
culated from 7 visits). The same associations of device
used and number of BP measurements per visit with
intra-individual SD were observed in the subgroups
that did and did not initiate antihypertensive medica-
tions (P<.05). For example, in the population who did
not initiate antihypertensive medications, the SD calcu-
lated from 7 visits was 6.9 mm Hg for the mean of 3
automated measurements, 7.6 mm Hg for a single
automated measurement, 5.8 mm Hg for the mean of
3 manual measurements, and 6.5 mm Hg for a single
manual measurement.
Number of Visits and Intra-Individual SD
In the overall TROPHY population, the average intra-
individual SD increased with the number of visits used
to calculate it regardless of how BP was measured
(Table III). The same pattern was observed in the par-
ticipants who did and those who did initiate antihy-
pertensive medications although the SD was lower in
the individuals who did not initiate medication (for
SD calculated from 7 visits P<.001 comparing those
who initiated antihypertensives and those who did
not) (Figure 1). When we censored participants at the
time of antihypertensive medication initiation, the
intra-individual SDs fell between those in the overall
population and those who never initiated antihyperten-
sive medications. As the number of visits increased,
more individuals were censored and the intra-individ-
ual SD more closely corresponded to the population
who never initiated antihypertensive medications.
In the overall TROPHY population, intra-individual
SD calculated from 3 visits differed, on average, by
41% from the values calculated using 18 visits, regard-
less of BP measurement device or number of BP mea-
surements per visit. With 7 visits, the intra-individual
SD differed by 21% to 24% from the values calcu-
lated using 18 visits.
In the simulated data, we observed a nonlinear pat-
tern of higher intra-individual SD with an increasing
number of visits (Figure 2). The SD approached the true
value of 8.5 mm Hg more quickly when BP had less
between-visit correlation. Based on the best fit to the
TABLE I. Baseline Characteristics of the Study










Age, mean (SD), y 48.9 (8.1) 49.8 (8.0) 47.3 (8.1)
Race, No. (%)
White 199 (88.4) 125 (90.6) 74 (85.1)
Black 13 (5.8) 8 (5.8) 5 (5.7)
Other 13 (5.8) 5 (3.6) 8 (9.2)








134 (4) 135 (4) 134 (4)
Diastolic blood pressure,
mean (SD), mm Hg
85 (4) 85 (4) 84 (4)
Abbreviation: SD, standard deviation.
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data, the fractional polynomial algorithm selected the
number of visits to powers )1 and 3 as the best predic-
tors of the intra-individual SD when there was no corre-
lation in BP between visits (SD=b0+b1n
)1+b2n
3, where
n=the number of visits used to calculated SD). The frac-
tional polynomial algorithm selected the powers )0.5
and )0.5 when the autocorrelation coefficient was 0.3,
)0.5 and 0.5 when the autocorrelation coefficient was
0.5, and natural logarithm and natural logarithm
squared when the autocorrelation coefficient was 0.7.
The number of visits and the square of the number of
visits appeared to fit the shape of the curves acceptably
in the range of 4 to 20 visits, based on the observation
that the residuals from this model were not associated
with the number of visits.
Number of Visits and Other Metrics of VVV
The range, maximum, coefficient of variation, average
real variability, and successive variation all increased
with the number of visits used to calculate the metric
(Table IV).
Timing of Visits and Intra-Individual SD
Increasing the time between BP measurements was asso-
ciated with higher intra-individual SD. In the overall
TROPHY population, using the mean of 3 manual
measurements at each visit, the average intra-individual
SD calculated from 7 consecutive visits (total time=18
months, median time between visits=3 months) was
6.8 mm Hg. In comparison, the average intra-individual
SD calculated from 7 visits spaced out across the 4-year
follow-up period (median time between visits=
8 months) was 7.5 mm Hg (P<.001 as compared with
7 consecutive visits). The SD calculated from all 18 vis-
its during the 4-year period was higher (7.7 mm Hg),
but the difference did not reach statistical significance
(P=.12).
In the simulated data without correlations between
visits, the intra-individual SD calculated from 7 con-
secutive visits and 7 visits spread out across the 100
visits were similar (8.2 mm Hg and 8.3 mm Hg).
When BP was assumed to be autocorrelated, the
TABLE II. Correlations Between Intra-Individual Standard Deviation in Systolic Blood Pressure Calculated Using
Automated and Manual Blood Pressure Measurement Devices from 7 Visits









Mean of 3 automated measurements 1
First automated measurement 0.92 1
Mean of 3 manual measurements 0.67 0.61 1
First manual measurement 0.61 0.57 0.92 1
No incident antihypertensive medication use (n=87)
Mean of 3 automated measurements 1
First automated measurement 0.87 1
Mean of 3 manual measurements 0.65 0.53 1
First manual measurement 0.60 0.49 0.85 1
Incident antihypertensive medication use (n=138)
Mean of 3 automated measurements 1
First automated measurement 0.93 1
Mean of 3 manual measurements 0.65 0.61 1
First manual measurement 0.59 0.57 0.94 1
TABLE III. Intra-Individual Standard Deviation in
Systolic Blood Pressure by Number of Visits,
Number of Measurements Per Visit, and Blood
















3 6.2 (3.6) 6.9 (3.8) 5.6 (3.2) 6.4 (3.7)
4 6.7 (3.5) 7.3 (3.5) 6.0 (3.1) 6.7 (3.4)
5 7.1 (3.3) 7.7 (3.3) 6.3 (2.9) 6.9 (3.1)
6 7.5 (3.2) 8.1 (3.2) 6.7 (2.9) 7.3 (3.0)
7 7.5 (3.0) 8.2 (2.9) 6.8 (2.6) 7.4 (2.7)
8 7.7 (2.9) 8.4 (2.9) 7.0 (2.9) 7.6 (3.0)
9 7.8 (2.7) 8.5 (2.7) 7.1 (2.8) 7.7 (2.8)
10 7.9 (2.6) 8.5 (2.6) 7.0 (2.6) 7.7 (2.7)
11 7.9 (2.5) 8.6 (2.5) 7.1 (2.5) 7.7 (2.6)
12 8.0 (2.5) 8.6 (2.4) 7.1 (2.5) 7.7 (2.5)
13 8.1 (2.6) 8.7 (2.5) 7.2 (2.5) 7.8 (2.5)
14 8.2 (2.6) 8.8 (2.5) 7.3 (2.5) 7.9 (2.5)
15 8.3 (2.6) 8.9 (2.5) 7.4 (2.5) 8.0 (2.4)
16 8.3 (2.6) 8.9 (2.5) 7.6 (2.4) 8.1 (2.4)
17 8.4 (2.6) 9.0 (2.5) 7.6 (2.5) 8.2 (2.4)
18 8.5 (2.6) 9.1 (2.5) 7.7 (2.5) 8.2 (2.4)
P for trend < .001 < .001 < .001 <.001
Values are expressed as mean intra-individual standard deviation
(standard deviation of the intra-individual standard deviation).
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intra-individual SD was higher when visits were not
consecutive. With an autocorrelation coefficient of 0.3,
the intra-individual SD from 7 consecutive visits was
7.6 mm Hg compared with 8.1 mm Hg when 7 mea-
surements were distributed across the 100 visits. Cor-
responding values were 7.0 mm Hg and 8.0 mm Hg
when the autocorrelation coefficient was 0.5 and 6.0
and 7.9 mm Hg when the autocorrelation coefficient
was 0.7.
DISCUSSION
In this study, we determined that design factors such
as the number and timing of visits with BP measure-
ments and the BP measurement device used influence
VVV. Of particular importance, the intra-individual
SD of BP increased with the number of visits used to
calculate it in a nonlinear fashion. We observed this
pattern in the overall TROPHY population, in sub-
groups defined by initiation of antihypertensive medi-
cations, and in simulated data. The same pattern of
increasing values with increasing number of visits was
also observed with the other metrics of VVV that we
examined: range, maximum, coefficient of variation,
average real variability, and successive variation.
Although we did not examine SD independent of the
mean, because it is indexed to SD, it would also
increase with an increasing number of visits. A higher
intra-individual SD and coefficient of variation of BP
with 7 visits compared with 3 visits was also noted
in a previous study.13 The association between the
number of visits used to calculate the SD and the SD
may be counterintuitive. However, it is a property of
the usual formula for the SD when the number of
measurements is small.14,15 As described in the statisti-
cal literature, the bias in the SD formula decreases
with increasing sample size and is related to the use of
the t rather than z distribution with small sample
sizes.14,15
When the number of visits used to calculate VVV is
not consistent across individuals, the dependence of
the SD on the number of visits could produce bias if
characteristics associated with the number of visits are
also associated with the outcome. For example, a
patient who visits a doctor frequently because of dia-
betes will have a larger number of BP measurements,
leading to a higher SD. Given the higher risk for out-
comes such as stroke or coronary heart disease among
individuals with diabetes, this could lead to a spurious
or exaggerated association between VVV and these
outcomes. Our results suggest that within a study the
same number of BP measurements should be used for
calculating VVV for all participants or that the num-
ber of measurements should be adjusted for statisti-
cally. The relationship between the number of visits
used to calculate intra-individual SD and the SD val-
ues appeared to be well approximated by the linear
and quadratic terms in the range of 4 to 20 visits.
Alternatively, formulas for and tables of correction
factors for the SD have been published14,15; however,
these correction factors are not widely used in the bio-
medical literature and, to our knowledge, have not
been used in research on VVV.
In large study populations, practical concerns limit
the number of study visits. In addition, the visits used
to calculate VVV should precede the follow-up period
during which events occur to ensure that VVV is not
affected by the events. This leads to a trade-off
between using more visits to calculate VVV, resulting
in a more accurate assessment of VVV but a shorter
follow-up period, or using fewer visits to calculate
VVV, resulting in a less accurate assessment of VVV
but a longer follow-up period for events to accrue.
FIGURE 1. Intra-individual standard deviations (SDs) of systolic blood
pressure (SBP) by number of visits among the overall population,
those who did not initiate antihypertensive medications, those who did
initiate antihypertensive medications, and censoring participants at the
time of initiation of antihypertensive medications. Intra-individual SD
calculated using the mean of 3 manual blood pressure measurements
at each visit. Results were similar when visit blood pressure was deter-
mined using the first measurement or an automated measurement
device.
FIGURE 2. Average intra-individual standard deviations (SDs) of sys-
tolic blood pressure (SBP) by number of visits in simulated populations
of 200 individuals with a mean blood pressure of 135 mm Hg and an
intra-individual SD of 8.5 mm Hg.
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Empirically, in one prior study, a larger number of vis-
its used to calculate the intra-individual SD resulted in
a higher hazard ratio for stroke.3 We had hoped to
determine the minimal number of visits needed to reli-
ably and accurately estimate VVV. Our results suggest
that there is no simple answer. In both the TROPHY
study population and simulated data, the calculated
intra-individual SD from 7 or 10 visits was less than
the true value (the SD calculated from all 18 visits in
the TROPHY population and the SD specified in the
simulation). Previous work has demonstrated that
higher intra-individual SD increases the number of
measurements needed to accurately calculate an indi-
vidual’s true mean BP.3 The effect of number of visits
on the estimated intra-individual SD was not reported.
The other factors we studied also influenced the
intra-individual SD. Visits spaced further apart were
associated with a higher SD. This could be the result
of underlying changes in BP due to aging, changes in
medication use or other behaviors, and seasonal pat-
terns in BP. Additionally within-person correlation in
BP declining over time results in a higher intra-individ-
ual SD, as shown in the simulations. In TROPHY, the
intra-individual SD calculated from 7 visits over
4 years was lower than the SD calculated from 18 vis-
its over the same time period, though the difference
did not reach statistical significance. This suggests that
both the number and spacing of visits impacts intra-
individual SD.
We found that averaging 3 BP measurements per
visit resulted in a lower SD. This is similar to previous
findings that averaging measurements across multiple
visits reduced within-person variability of BP and that
intra-individual variability was lower in when calcu-
lated using 24-hour average BP than clinic BP.13,16
However, the SD calculated from a single measure-
ment per visit was highly correlated with the SD
calculated from the mean of 3 measurements per visit.
This implies that if the intent is to rank individuals on
degree of VVV, a single BP measurement per visit may
provide similar information to the mean of three
measurements per visit. However, when individuals
have the same underlying degree of variability, those
with more measurements per visit will have a lower
intra-individual SD. This could lead to bias if the num-
ber of BP measurements taken per visit is related to
the individuals’ health status or other characteristics.
To avoid this problem, the same number of measure-
ments per visit should be used for all participants in a
study.
Finally, the SD was higher when automated BP mea-
surement devices were used as compared with manual
devices. One possible explanation is that the errors
introduced by oscillometric BP monitoring with auto-
mated devices led to excess variability. Alternatively,
with manual measurement, observer bias and the prac-
tice of recording only even values may have lead to a
reduction in variability. Manual BP measurements by
well-trained observers continue to be recommended
for routine clinical use.17
The observed SD of SBP was lower in this popula-
tion than in other described populations.1–5 As we
have shown, comparing the variability of BP across
populations is complicated by the influence of the
study design. Additionally, individuals with higher SBP
tend to have higher variability of SBP.3 The TROPHY
TABLE IV. Range, Maximum, Coefficient of Variation, Successive Variation, and Average Real Variability by









3 10.7 (6.1) 134 (9) 4.4 (2.5) 8.2 (4.4) 7.1 (3.8)
4 13.4 (6.9) 135 (9) 4.7 (2.4) 8.5 (4.0) 7.2 (3.4)
5 15.5 (7.1) 136 (9) 4.9 (2.2) 8.8 (3.9) 7.3 (3.2)
6 17.7 (7.6) 138 (10) 5.2 (2.1) 9.0 (3.8) 7.4 (3.1)
7 19.1 (7.5) 138 (10) 5.3 (1.9) 9.2 (3.8) 7.5 (3.0)
8 20.6 (8.9) 139 (11) 5.4 (2.1) 9.4 (3.9) 7.6 (3.0)
9 21.6 (9.0) 139 (10) 5.5 (2.0) 9.3 (3.7) 7.5 (2.8)
10 22.1 (8.9) 140 (10) 5.5 (1.9) 9.2 (3.5) 7.4 (2.7)
11 23.0 (9.0) 140 (10) 5.5 (1.9) 9.3 (3.4) 7.4 (2.6)
12 24.1 (9.2) 140 (10) 5.6 (1.8) 9.3 (3.3) 7.4 (2.5)
13 24.8 (9.5) 141 (10) 5.6 (1.8) 9.4 (3.2) 7.5 (2.5)
14 25.6 (9.8) 141 (10) 5.7 (1.9) 9.6 (3.2) 7.6 (2.5)
15 26.4 (9.7) 142 (10) 5.8 (1.8) 9.7 (3.2) 7.7 (2.4)
16 27.4 (10.0) 142 (10) 5.9 (1.8) 9.7 (3.1) 7.7 (2.4)
17 28.2 (10.2) 142 (10) 6.0 (1.9) 9.7 (3.1) 7.7 (2.4)
18 28.9 (10.4) 142 (10) 6.1 (1.9) N ⁄ Ab N ⁄ Ab
P for trend <.001 <.001 <.001 <.001 .04
Values are expressed as mean value (standard deviation). aBlood pressure assessed as the mean of 3 manual measurements per visit. bThe formulas
for successive variation and average real variability require n+1 visits to calculate.
Official Journal of the American Society of Hypertension, Inc. The Journal of Clinical Hypertension Vol 14 | No 11 | November 2012 749
Visit-to-Visit Variability of Blood Pressure | Levitan et al.
population had relatively low BP in a narrow range,
which likely contributed to the observed low SD of
SBP. Previous studies have included individuals with
frank hypertension and individuals with existing
cardiovascular disease.1–5
In the TROPHY placebo arm, 61% of participants
initiated antihypertensive medications. We observed
higher SD in the participants who initiated antihyper-
tensive medications than those who did not. A
contributing factor could have been the decision rule
used to initiate antihypertensive therapy (3 visits with
SBP 140 mm Hg or diastolic BP 90 mm Hg, 1
visit with SBP 160 mm Hg or diastolic BP
100 mm Hg, or target organ damage or other clini-
cal reasons to start antihypertensive therapy as deter-
mined by the investigators). This rule could have had
the effect of selecting participants with higher VVV
for treatment.
STUDY STRENGTHS AND LIMITATIONS
The use of high-quality BP measurements using auto-
mated and manual devices from a trial population ran-
domized to placebo and followed for 4 years is a
major strength of this study. However, there are also
limitations including the initiation of antihypertensive
medications in the majority of the participants. The
current study was restricted to individuals with BP in
a narrow, prehypertensive range at baseline and the
impact of number of visits, timing of visits, and device
used to measure BP on VVV should be investigated in
additional populations, including hypertensive individ-
uals receiving treatment. We focused primarily on
intra-individual SD, and a more thorough investigation
of other metrics is warranted.
CONCLUSIONS
The current study demonstrates that VVV is influenced
by the number of visits used to calculate it, the timing of
those visits, the BP measurement device, and the number
of measurements per visit. It is important to recognize
that factors besides intrinsic VVV may result in differ-
ences in VVV between study populations. When investi-
gating the association of VVV and outcomes in a study
population, VVV should be calculated using the same
number of visits for all individuals or VVV should be
adjusted for the number of visits used in its calculation.
The current study indicates that care must be taken in
the implementation and interpretation of VVV as this
line of research matures.
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